Hyung-Jin Cho

Hyung-Jin Cho

Auto-generated profile, based on publicly available information

Hyung-Jin Cho

Department of Surgery, Division of Vascular and Transplant Surgery, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
MKMi-Hyeong Kim
Mi-Hyeong Kim
JHJeongkye Hwang
Jeongkye Hwang
HCHyung-Jin Cho
Hyung-Jin Cho
KKKyung-Jai Ko
Kyung-Jai Ko
KJKang Woong Jun
Kang Woong Jun
JHJeongkye Hwang
Jeongkye Hwang
Kim MH, et al. Ann Surg Treat Res. 2021 Nov;101(5):291-298. https://doi.org/10.4174/astr.2021.101.5.291

15 July 2022 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
HCHyung-Jin Cho
Hyung-Jin Cho
JYJu-Hwan Yoo
Ju-Hwan Yoo
MKMi-Hyeong Kim
Mi-Hyeong Kim
KKKyung-Jai Ko
Kyung-Jai Ko
KJKang-Woong Jun
Kang-Woong Jun
JHJeong-Kye Hwang
Jeong-Kye Hwang

31 January 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
HCHyung Jin Cho
Hyung Jin Cho
ILIn Kyu Lee
In Kyu Lee
YLYoon Suk Lee
Yoon Suk Lee
SYSang Seob Yun
Sang Seob Yun
SPSun Cheol Park
Sun Cheol Park
CLChul Seung Lee
Chul Seung Lee

1 November 2022 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
KJKang Woong Jun
Kang Woong Jun
JHJeongkye Hwang
Jeongkye Hwang
KKKyung-Jai Ko
Kyung-Jai Ko
HCHyung-Jin Cho
Hyung-Jin Cho
MKMi-Hyeong Kim
Mi-Hyeong Kim
JHJeongkye Hwang
Jeongkye Hwang
Jun KW, et al. Ann Surg Treat Res. 2022 Nov;103(5):297-305. https://doi.org/10.4174/astr.2022.103.5.297

21 November 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
DPDong Jin Park
Dong Jin Park
MKMihyeong Kim
Mihyeong Kim
HCHyungjin Cho
Hyungjin Cho
JKJung soo Kim
Jung soo Kim
JHJeongkye Hwang
Jeongkye Hwang
JLJehoon Lee
Jehoon Lee
Background: Tacrolimus is a cornerstone immunosuppressant in kidney transplantation, but its narrow therapeutic index and marked inter-patient variability complicate dose optimization. Conventional therapeutic drug monitoring (TDM) relies on empirical adjustments that often overlook individual pharmacokinetics. Machine learning (ML) offers a precision dosing alternative by integrating diverse clinical and biochemical variables into predictive models. Methods: We retrospectively analyzed 1351 data points from 87 kidney transplant patients at Eunpyeong St. Mary’s Hospital (April 2019–November 2023). Clinical, demographic, and laboratory information, including tacrolimus trough levels and dosing history, were extracted from electronic medical records. Four predictive models—XGBoost, CatBoost, LightGBM, and a multilayer perceptron (MLP)—were trained to forecast next-day tacrolimus concentrations, and model serum creatinine level performance was evaluated using R-squared (R2), mean absolute error (MAE), and root-mean-squared error (RMSE). An ensemble model with weighted soft voting was applied to enhance predictive accuracy, and model interpretability was assessed using SHapley Additive exPlanations (SHAP). Results: The ensemble model achieved the best overall performance (R2 = 0.6297, MAE = 1.0181, RMSE = 1.2999), outperforming all individual models, whereas the MLP model showed superior predictive power among single models, reflecting the significance of nonlinear interactions in tacrolimus pharmacokinetics. SHAP analysis highlighted prior tacrolimus levels, cumulative dose, renal function markers (eGFR level, serum creatinine level), and albumin concentration as the most influential predictors. Conclusions: We present a robust ML-based algorithm for tacrolimus dose optimization in hospitalized kidney transplant recipients. By improving predictions of tacrolimus concentrations, the model may help reduce inter-patient dose variability and lower the risk of nephrotoxicity, supporting safer and more individualized immunosuppressive management. This approach advances AI-driven precision medicine in transplant care, offering a pathway to safer and more effective immunosuppression.

26 August 2025 in Annals of Coloproctology
Verified
Journal Article
Open access
YCYoung Sun Choi
Young Sun Choi
HCHyung Jin Cho
Hyung Jin Cho
CLChul Seung Lee
Chul Seung Lee
DLDong Geun Lee
Dong Geun Lee
CCChoon Sik Chung
Choon Sik Chung
TKTae Gyu Kim
Tae Gyu Kim
Age and postoperative complications are known risk factors for venous thromboembolism (VTE). Minimally invasive surgery and Enhanced Recovery After Surgery (ERAS) protocol has been implemented to reduce these risks. The purpose of this study was to assess the short- and long-term effects of a VTE prophylaxis program using the Caprini score in elderly patients undergoing minimally invasive colorectal cancer surgery with the ERAS protocol. This retrospective cross-sectional study included 1,043 colorectal cancer patients requiring surgery from January 2017 to December 2019, divided into a control group (≤75 years) and an elderly group (>75 years), with 827 and 216 patients, respectively. The primary outcome was the incidence of VTE; secondary outcome was the incidence of postoperative complications, particularly bleeding. The incidence of VTE was 1.5% in the control group and 3.7% in the elderly group (P=0.061). Five patients (0.5%) experienced symptomatic VTE, and the Caprini score for all VTE patients was ≤8 points; thus, only mechanical prophylaxis was used. In the multivariable logistic regression, the Caprini score (P=0.024) and cancer stage (P=0.004) were selected. The odds ratios (95% confidence interval) of the Caprini score and TNM staging were 1.758 (1.078-2.867) and 6.152 (2.045-26.510), respectively. When the ERAS protocol was used for patients with colorectal cancer as perioperative care, the VTE risk was lower than that estimated by the Caprini score. Given that age is a recognized risk factor for major bleeding, criteria for the use of anticoagulation to prevent VTE, particularly in elderly patients, should be carefully evaluated, considering both the bleeding risks and the potential benefits of pharmacologic prophylaxis. Trial registration: Clinical Research Information Service (CRIS; cris.nih.go.kr) identifier: KCT0007804.